Single-Center Real World Study of Everolimus and Exemestane in HR+/HER2− Metastatic Breast Cancer Following CDK4/6 Inhibitor Therapy

Background: Hormone receptor-positive (HR+), HER2− negative metastatic breast cancer (MBC) is the most common subtype of advanced breast cancer. Resistance to endocrine therapy often develops, particularly after CDK4/6 inhibitors. Everolimus, an mTOR inhibitor, may restore hormone sensitivity, but r...

Descripció completa

Dades bibliogràfiques

Autors principals:	Yunus Emre Altıntaş, Oğuzcan Kınıkoğlu, Deniz Işık, Aziz Batu, Ayberk Bayramgil, Büşra Niğdelioğlu, Uğur Özkerim, Sıla Öksüz, Heves Sürmeli, Nedim Turan, Hatice Odabaş
Format:	Artigo
Idioma:	Inglês
Publicat:	MDPI AG 2025-09-01
Col·lecció:	Current Oncology
Matèries:	everolimus exemestane CDK4/6 inhibitor resistance mTOR inhibition advanced breast cancer
Accés en línia:	https://www.mdpi.com/1718-7729/32/9/503
Etiquetes:	Afegir etiqueta Sense etiquetes, Sigues el primer a etiquetar aquest registre!